Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu
Ghanshyam S. Yadav, Dana M. Roque, Stefania Bellone, Diego Manavella, Tobias M.P. Hartwich, Margherita Zipponi, Justin Harold, Joan Tymon‐Rosario, Levent Mutlu, Gary Altwerger, Gulden Menderes, Elena Ratner, Natália Buza, Pei Hui, Gloria S. Huang, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Ludmil B. Alexandrov, Alessandro D. Santin
Topics & Concepts
OlaparibNeratinibCancer researchMedicinePARP inhibitorHER2/neuOncologyInternal medicineCancerBiologyTrastuzumabBreast cancerPoly ADP ribose polymeraseGeneBiochemistryPolymerasePARP inhibition in cancer therapyAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer Research